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Abstract
Objective
To determine whether the assessment of brain white matter lesion (WML) central veins
diﬀerentiate patients with primary progressive MS (PPMS) from relapsing-remitting MS
(RRMS) and ischemic small vessel disease (SVD) using 3T MRI.
Methods
In this cross-sectional study, 71 patients with PPMS, RRMS, and SVD were imaged using
a T2*-weighted sequence. Two blinded raters identiﬁed the total number of WMLs, proportion
of WMLs in periventricular, deep white matter (DWM) and juxtacortical regions, and pro-
portion of WMLs with central veins in all patient groups. The proportions were compared
between disease groups, including eﬀect sizes. MS or SVD was categorized using a threshold of
≥40%WMLs with central veins as indicative ofMS. Interrater and intrarater reproducibility was
calculated.
Results
The mean proportion of WMLs with central veins was 68.4% in PPMS, 74.3% in RRMS, and
4.7% in SVD. The diﬀerence in proportions between PPMS and SVD groups was signiﬁcant
(p < 0.0005; eﬀect size: 3.8) but not signiﬁcant betweenMS subtypes (p = 0.3; eﬀect size: 0.29).
Distribution of WMLs was similar across both MS groups, but despite SVD patients having
more DWM lesions than PPMS patients, proportions of WMLs with central veins remained
low (2.75% in SVD; 62.5% in PPMS). Interrater and intrarater reproducibility comparing
proportions of WMLs with central veins across all patients was 0.86 and 0.90, respectively.
Level of agreement between the proportion of WML central veins and established diagnosis
was 0.84 and 0.82 for each rater.
Conclusions
WML central veins could be used to diﬀerentiate PPMS from SVD but not between MS
subtypes.
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Approximately 15% of patients with MS develop progressive
symptoms from the onset; primary progressive MS (PPMS)1,2
can pose more diagnostic challenges compared to relapsing-
remitting MS (RRMS).3,4 The presence of white matter
lesions (WMLs) becomes more frequent with age,5 as such
the risk of misdiagnosis of MS rises. Occasionally, the location
of WMLs is helpful in distinguishing MS from ischemic small
vessel disease (SVD), a common MRI mimic of MS.6
SometimesWMLs in SVD can aﬀect the same brain regions as
MS, fulﬁlling dissemination in space MS MRI criteria.7 In
SVD, deep white matter (DWM) and subcortical lesions are
the most common areas for WMLs,8 although periventricular
(PV) lesions can also occur.9 WMLs in the DWM and
juxtacortical (JC) areas are most likely to cause diagnostic
confusion between MS and SVD.10
T2*-weighted MRI allows visibility of small veins within
WMLs secondary to increased deoxyhemoglobin concen-
trations. This represents the imaging equivalent of in-
ﬂammatory activity surrounding a vein on histology.11,12
Studies in RRMS have shown its potential to diﬀerentiate
RRMS from neuromyelitis optica13–15 and SVD at 3 and
7T.10,16,17 Studies at 7T showed PPMS had similar pro-
portions ofWMLs with central veins compared to RRMS.16,18
We used 3T T2* to (1) determine if the proportion of WMLs
with central veins in PPMS is as high as RRMS and (2)
determine if the diﬀerence between the proportion of WMLs
with central veins in PPMS and SVD is as signiﬁcant as seen in
RRMS.
Methods
Patient selection
All patients recruited were adults over the age of 18 years who
attended the MS or general neurology clinics at Nottingham
University Hospitals NHS Trust, United Kingdom with
a conﬁrmed diagnosis of PPMS, RRMS, or SVD. Consecutive
patients with PPMS seen in the MS clinic were invited for this
study if they had at least one brain lesion on their clinical T2
or ﬂuid-attenuated inversion recovery (FLAIR) MRI scan.
RRMS patients were part of a wider study looking at the use of
central veins in MS. All patients were diagnosed by experi-
enced MS neurologists and were regularly followed up for
their MS. All patients had typical MRI ﬁndings, supported by
a consultant neuroradiology report, with some having CSF
testing for oligoclonal bands. Time of initial diagnoses span-
ned from prior to the year 2000, as a consequence Poser and
McDonald criteria 2001–2010 were initially used but all of
them fulﬁll the 2017 criteria.19
All patients with a diagnosis of SVD were referred to the
neurology service by their general practitioner for a variety of
symptoms. The diagnosis was based on clinical evaluation by
a consultant neurologist, ruling out symptoms suggestive of
demyelination or another white matter disease and identiﬁ-
cation of vascular risk factors such as a history of hypertension,
hypercholesterolemia, diabetes mellitus, smoking, and high
body mass index. Some of these patients had supportive
laboratory ﬁndings (blood tests, e.g., checking cholesterol,
autoimmune screen, and sometimes CSF testing to exclude
possible demyelination). Each patient had an MRI brain scan
reported by a consultant neuroradiologist conﬁrming the
appearance of the scan was in keeping with SVD.
Exclusion criteria for both groups included patients who had
other autoimmune diseases that could potentially also cause
WMLs and patients who were pregnant.
Standard protocol approvals, registrations,
and patient consents
Written informed consent from all patients was obtained
before inclusion, and the study was approved by the local
research ethics committee.
MRI protocol
MRI was performed using a 3T Achieva (Philips Healthcare,
Best, The Netherlands) with a 32-channel receive-only head
coil. The protocol consisted of a high-resolution 3D T2*-
weighted gradient echo scan with a high echo planar imaging
factor of 15.20 The matrix was 448 × 448 × 336 with a non-
interpolated voxel size of 0.55 × 0.55 × 0.55 mm. Parallel
imaging factors of 2 were used in both phase encoding
directions. In addition, the water-only excitation ﬂip angle was
10 degrees, eﬀective echo time 29 ms, repetition time 54 ms, 2
averages, duration 254 seconds.
Image analysis
Only T2* images were used for the analysis. Images were saved in
a DICOM format and then converted to NIfTI format.21 Each
brain T2* scan was cut into 8 blocks using an in-house algorithm
(A.P.). This was done to prevent the brain being seen in its
entirety, in an attempt to blind the raters as much as possible to
the overall pattern of WMLs with central veins throughout the
brain. We aimed to prevent lesion location and the presence of
a vein in some lesions inﬂuencing the “detection” of veins in other
lesions in the same brain, revealing the diagnosis of MS or SVD.
In-house image analysis software NeuROI (nottingham.ac.uk/
research/groups/clinicalneurology/neuroi.aspx) was used to
identify WMLs manually by raters blinded to the clinical
Glossary
DWM = deep white matter; ICC = intraclass correlation coeﬃcient; IQR = interquartile range; JC = juxtacortical; PPMS =
primary progressive MS; PV = periventricular; RRMS = relapsing-remitting MS; SVD = small vessel disease; WML = white
matter lesion.
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diagnoses. A WML central vein was judged as present if it
appeared as a black hypointense line (running along the long
axis of the WML) or a hypointense dot within the centre of
a WML surrounded by a hyperintense ring. This had to be in at
least 2 of 3 orthogonal planes. All WMLs were more than 3
voxels in diameter with demarcated borders. Conﬂuent WMLs
withmultiple veins coursing through themwere not counted, as
sometimes it was diﬃcult to identify a deﬁnite central vein.
Therefore, the vein also had to be located within the centre of
the WML irrespective of the lesion shape.22 This applied to
WMLs in both the MS and the SVD groups. Total WML
numbers, WML central vein numbers, and the proportion of
WMLswith central veins were calculated for each block of brain
volume and total brain volume. The location of each WML in
the brain was also assessed by one rater (A.P.R.S.) and classiﬁed
as (1) PV if one border of the WML was in contact with the
ventricular surface; (2) JC if one border of the WML was in
contact with cortical grey matter; (3) DWM if the WML did
not meet either of the above 2 criteria.23,24 Infratentorial lesions
were not included in the analysis because of limitations of T2*
in detecting lesions in this area (more noise and sometimes it
was diﬃcult to delineate lesions from the CSF in between the
folia of the cerebellum, which is also hyperintense). Each scan
was ﬁnally classiﬁed asMS if 40% or more ofWMLs had central
veins or as SVD if less than this. This threshold in previous
studies allowed a clear diﬀerentiation of the 2 groups.16,25
To determine interrater reproducibility of the proportion of
WMLs with central veins for each patient (i.e., can each rater
determine a similar proportion of WMLs with central veins),
a second blinded rater (Y.F.) analyzed 50% of the T2* scans.
Additionally to test the intrarater reproducibility, 2 months
after the initial assessment, 2 further procedures were fol-
lowed by blinded assessor (A.P.R.S.); ﬁrst, 71 randomly se-
lected brain blocks (one from each subject) were assessed for
WML number and proportion of WMLs with central veins.
Second, 25% of whole brain scans were reviewed again to
establish intrarater reproducibility of the whole brain WML
assessment and of the disease classiﬁcation.
Statistical analysis
Mean values with SDs or medians and interquartile ranges
(IQRs) for nonparametric data are quoted. Histograms were
used to determine normal and nonnormal distributed data. A
Mann-Whitney U test was used to compare nonnormal data
and an independent t test for normally distributed data. An
intraclass correlation coeﬃcient (ICC) 2-way random model
was used to determine the interrater and intrarater absolute
agreement of identifying the proportion of WMLs with cen-
tral veins. The agreement between 2 blinded raters in terms of
the diagnosis (MS or SVD) based on using the presence of
WML central veins alone was calculated with a Cohen kappa
coeﬃcient, as was the agreement between each rater and the
known, established diagnosis. Eﬀect sizes were calculated
using Cohen d. Statistical signiﬁcance was set at p < 0.05.
Statistical analyses were performed using Statistical Package
for the Social Sciences (IBM SPSS 22).
Data availability
All anonymized raw data can be provided by request from any
qualiﬁed investigator.
Results
Demographics
Seventy-one patients were scanned; 32 patients with PPMS
(14 female and 18 male patients), 23 with RRMS (13 female
and 10 male patients), and 16 with SVD (8 female and 8 male
patients). The mean age of the PPMS group was 55.4 ± 9.5
years (range, 35–73 years) and mean expanded disability
status scale (EDDS) was 5.6 (range, 2–7); mean age was 41.1
± 12.3 years (range, 18–64 years) and mean EDSS was 2.7
(range, 0–6) in the RRMS group; mean age was 50.9 ± 9.6
years (range, 38–75 years) in the SVD group. The diﬀerence
in age between PPMS and SVD patients was not signiﬁcantly
diﬀerent (p = 0.14, eﬀect size: 0.47), although it was between
the RRMS and the PPMS groups (p < 0.0005, eﬀect size: 1.3).
Median disease duration, taken as the time from a conﬁrmed
diagnosis by a neurologist to the date of the T2* scan, was 36
months (IQR, 2–144) in the RRMS group and 43.5 months
(IQR, 25–63) in the PPMS group (p = 0.93).
PPMS and SVD
Comparisons for these 2 groups are summarized in table 1,
with examples of the central vein visibility in PPMS and ab-
sence in SVD shown in ﬁgure 1. A total of 1,501 WMLs were
detected between both groups. SVD patients had a higher
number of WMLs (median: 35 [17–44.8]) than PPMS
patients (median: 17 [8–44.5]). Although this diﬀerence was
not statistically signiﬁcant, there was a trend toward signiﬁ-
cance (mean diﬀerence: −18; 95% CI, −34.5 to −1.5; p =
0.06). The mean proportion of WMLs with central veins in
the PPMS group was much higher than in those with SVD
(table 1 and ﬁgure 2).
PPMS and RRMS
MRI results for the MS cohorts are summarized in table 2,
with examples of the central vein visibility in RRMS shown in
ﬁgure 1. The total number of WMLs identiﬁed in both groups
was 1,956. As described in the table, the median WMLs in the
PPMS group was lower than in RRMS (p = 0.03). The mean
proportion of WMLs with central veins in all locations for the
PPMS group was similar to the RRMS patients (68.4% and
74.3%, respectively; p = 0.3; eﬀect size: 0.29). The diﬀerences
in proportions of WMLs with central veins in the PV, DWM,
and JC regions are summarized in table 2 and ﬁgure 3.
A signiﬁcant ﬁnding was that the proportion of WMLs that
were in the DWM region of the SVD group was higher than
the PPMS patients.
However, the proportion of these DWM lesions with central
veins was much lower, with only 2.75% having central veins in
the SVD cohort compared to 62.5% in PPMS (ﬁgure 3).
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Interrater reproducibility
Interrater ICC was high when the proportion of WMLs with
central veins was compared between both raters (0.86; 95%
CI, 0.56–0.94; p < 0.0005). The level of agreement between
using the proportion of WMLs with central veins alone
(≥40% indicative of MS) to categorize a scan as MS or SVD,
and the established diagnosis was good for both raters (rater
Y.F.: 0.84; 95% CI, 0.54–1; p < 0.0005 and rater A.P.R.S.:
0.82; 95% CI, 0.67–0.97; p < 0.0005).
Intrarater reproducibility
High values were found for intrarater reproducibility (0.90;
95% CI, 0.73–0.96; p < 0.0005).
Intrarater reproducibility was tested again 2 months after the
initial assessment by A.P.R. Samaraweera. Seventy-one ran-
domly selected brain blocks (1 from each subject) were
assessed for WML number and proportion of WMLs with
central veins and compared to the ﬁrst attempt. For WML
numbers, ICC was 0.99 (95% CI, 0.98–0.99, p < 0.0005), and
for the proportion of WMLs with central veins, ICC was 0.95
(95% CI, 0.91–0.97, p < 0.0005).
Classification of MS or SVD based on 40%
threshold of the central vein marker
Testing if both raters agreed with each other about the cate-
gorization of MS and SVD for each scan showed moderate
agreement (0.54; 95% CI, 0.15–0.93; p = 0.001). Twenty-ﬁve
percent (18/71) of all whole brain scans were reviewed again
by one rater (A.P.R.S.), and the categorizations of MS and
SVD, and the established diagnoses were compared between
both attempts by this rater (0.73; 95% CI, 0.38–1; p = 0.001).
Discussion
We found that WML central veins were present in patients
with PPMS using a T2*-weighted sequence at 3T MRI, and
hence suggest that the central vein marker could be used as
supportive criterion in the diagnosis of PPMS. This has the
potential to inﬂuence patient care promoting earlier diagnosis
of PPMS, with early initiation of treatment in PPMS being
shown to be more likely to produce greater beneﬁts.26
The new diagnostic criteria for MS19 are already advancing
early diagnosis in the clinical setting, but they were not de-
veloped to diﬀerentiate MS from other conditions. PPMS is
more diﬃcult to diagnose than RRMS, due to it insidious
onset, older age at presentation (and as a consequence greater
number of diﬀerential diagnoses), less brain WMLs on MRI,
and WMLs which can be mistaken for ischemic WMLs.27 As
a result, patients with a suspicion of progressive MS are more
likely to have a longer time from symptom onset to diagnostic
conﬁrmation4 and have additional investigations, such as
spinal cord MRI, CSF testing, and evoked potentials.28
Of all the diﬀerential MRI diagnoses, distinguishing MS from
SVD and other incidental WMLs detected on MRI is one of
Table 1 Brain WML central veins by region in the PPMS and SVD groups
PPMS (n = 32) SVD (n = 16) Difference p Value
Effect
sized
Median WML numbers
(median)
17 (IQR, 8%–44.5%) 35 (IQR, 17%–44.8%) −18 (95% CI, −34.5 to −1.5) 0.06
Proportions of WMLs with
central veins (mean)
68.4% ± 23.1% (SD) 4.7% ± 4.3% (SD) 63.7% (95% CI, 55.1 to 72.3) 0.0005c 3.8
Proportion of WMLs which
were PV (median)
45.4% (IQR, 23.9%–53.8%) 3.7% (IQR, 0%–9.9%) 41.8% (95% CI, 35.9 to 47.7) 0.0005
Proportion of WMLs which
were DWM (median)
45.8% (IQR, 35.6%–60.9%) 93.7% (IQR, 83.2%–98.4%) −47.9% (95% CI, −57.6 to −38.2) 0.0005
Proportion of WMLs which
were JC (median)
6.9% (IQR, 0%–17.6%) 0% (IQR, 0%–5%) 6.9% (95% CI, 1.1 to 12.7) 0.006
Proportion PV WMLs with
central veins (median)b
80% (IQR, 65.7%–100%) 0% (IQR, 0%–100%) 80% (95% CI, 65.3 to 94.7%) 0.0005
Proportion DWM WMLs with
central veins (median)b
62.5% (IQR, 27.5%–88.1%) 2.75% (IQR, 0%–6.28%) 59.8% (95% CI, 42 to 77.5) 0.0005
Proportion JC WMLs with
central veins (median)b
42.9% (IQR, 0%–100%) 0% (N/A)a 42.9% (95% CI, 9.5 to 76.2) 0.0005
Abbreviations: DWM = deep white matter; IQR = interquartile range; JC = juxtacortical; N/A = not applicable; PPMS = primary progressive MS; PV = peri-
ventricular; SVD = small vessel disease; WML = white matter lesion.
a No JC lesions had a central vein in the SVD group, and so an IQR cannot be quoted.
b The proportion of WMLs with central veins according to their location was calculated using the total number of WMLs in the same location as the
denominator.
c Calculated using t test.
d Calculated using Cohen d.
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the most common.6,29 This becomes more challenging
when the clinical presentation is not with a relapsing pat-
tern, but with progressive neurologic symptoms, as in
PPMS. We have found that WML central veins could be
used to distinguish PPMS from SVD, as it has been shown
with RRMS in multiple studies before.10,13,14,16,17,25,30,31
Although SVD patients had more WMLs on average than
patients with PPMS, we found that this had no diagnostic
value. As expected, the majority of the WMLs in the SVD
group were in the DWM, in keeping with the literature on
the distribution of lesions in SVD.10,32–34 Although this
reached statistical signiﬁcance at the group level, the WML
location was not able to diﬀerentiate PPMS and SVD
(results not shown here). In this study, we speciﬁcally
evaluated sections of the brain separately, so the observer
could not be inﬂuenced by the presence of veins in other
WMLs of the same brain or overtly be inﬂuenced by the
location of the WMLs.
The clinically important diagnostic ﬁnding of this study was
the stark contrast between the proportion of WMLs with
central veins in the PPMS group (68.4%) and the SVD
patients (4.7%). Even the more common DWM lesions of the
SVD group had fewer central veins compared to DWM
lesions of PPMS patients (approximately 3% vs 62%).
The central vein marker has been found to be diagnostically
useful in MS before; however, most studies have reported on
RRMS patients that usually pose less of a diagnostic challenge
than PPMS. Until now, to our knowledge, 2 studies have
reported on a small number of PPMSpatients withT2*-weighted
imaging at 3T.17,35 Our study conﬁrmed both the pathologic
ﬁndings of perivenous demyelination in PPMS, and ultra-high-
ﬁeld MRI results.16,18
We found that all PPMS and RRMS patients studied had
similarly high proportions of WMLs with central veins, and
higher than all individuals with SVD. This has been shown in
smaller cohorts in previous studies only at 7T.18 Like previous
reports, our work has not been able to diﬀerentiate the 2 MS
subtypes apart using the central vein marker, which is not
surprising considering the histopathologic similarities of the 2
MS subtypes. Although the number of WMLs was, as a group,
lower in the PPMS patients, the location of WMLs in the
supratentorial brain was similar across both MS groups, with
most WMLs in the PV and DWM regions. WMLs in the PV
region had high numbers of central veins (80% of PV lesions
in PPMS and 90% in RRMS). This would be expected because
of the high venous density in the PV distribution, caused by
deep medullary veins draining toward subependymal veins of
the lateral ventricles.36 Furthermore, over 60% of DWM
Figure 1White matter lesion central vein visibility in MS and absence in small vessel disease (SVD)
(A and B) Two different patients with
primary progressive MS, showing
a deep white matter (DWM) lesion
with a central vein (A) and periven-
tricular lesion with a central vein (B).
(C) A patient with relapsing-remitting
MS showing 3 DWM lesions each with
a central vein. (D) A patient with SVD
showing 2 DWM lesions with no cen-
tral vein.
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lesions in both MS groups also had central veins. Any small
diﬀerences in the proportions of PV, DWM, and JC lesions
with central veins between PPMS and RRMS patients were
not signiﬁcant, reinforcing that lesion location and the
presence of central veins cannot distinguish the 2 subtypes.
This also is in keeping with the evidence suggesting similari-
ties in the pathophysiology of WML formation in these 2
subtypes of MS.
The diagnostic rule of using 40% of WMLs with central veins
as a cut-oﬀ for categorizing MS allowed high agreement with
the established diagnoses for both raters. However, moderate
agreement was shown when using this rule to determine if
both raters agreed with each other about the established di-
agnosis. We can only hypothesize that identifying all WMLs
and central veins may lead to more error (potentially mis-
taking CSF, perivascular spaces, nonspeciﬁc lesions, and
cortex as demyelinating lesions). More studies will be needed
to assess if identifying a subset of WMLs with central veins is
more accurate.31
Our study cohorts were derived from a typical UK neurosci-
ence centre with a large outpatient clinical setting, combining
both general neurology and MS clinics. The demographics
were as anticipated. The mean age of our RRMS cohort was
lower than the PPMS group, with slightly more females than
males in the RRMS group and the opposite in the PPMS
cohort. Our PPMS patients had a higher level of disability
compared to RRMS patients. WML numbers were also lower
in the PPMS group in keeping with the previous literature.1,37
Some limitations of this study should be noted. First, there
was a diﬀerence in age between the PPMS and RRMS group,
with a mean diﬀerence of 14.2 years. As nonspeciﬁcWMLs are
Figure 2 Frequency of the proportion of total WMLs with
central veins in PPMS, RRMS, and SVD
Results were derived from the analysis of one rater (A.P.R.S.) who analyzed
all the blinded scans. PPMS = primary progressive MS; RRMS = relapsing-
remitting MS; SVD = small vessel disease; WML = white matter lesion.
Table 2 Brain WML central veins by region in the PPMS and RRMS groups
PPMS (n = 32) RRMS (n = 23) Difference p Value
Effect
sizec
Median WML numbers
(median)
17 (IQR, 8–44.5) 39 (IQR, 13%–57%) −22 (95% CI, −41.2 to −2.8) 0.03
Proportions of WMLs with
central veins (mean)
68.4% ± 23.1% (SD) 74.3% ± 17.1% (SD) −5.9% (95% CI, −17.3 to 5.5) 0.3b 0.29
Proportion of WMLs which
were PV (mean)
42.8% ± 23.3% (SD) 41.1% ± 15.9% (SD) 1.7% (95% CI, −9.6 to 12.9) 0.77b 0.08
Proportion of WMLs which
were DWM (mean)
46.5% ± 23% (SD) 47.2% ± 14.8% (SD) −0.8% (95% CI, −11.7 to 10.2) 0.89b 0.03
Proportion of WMLs which
were JC (median)
6.9% (IQR, 0%–17.6) 9.1% (IQR, 7.7%–12.3%) −2.2% (95% CI, −7.8 to 3.4) 0.36
Proportion PV WMLs with
central veins (median)a
80% (IQR, 65.7%–100%) 90% (IQR, 80%–100%) −10% (95% CI, −26.9 to 6.9) 0.23
Proportion DWM WMLs with
central veins (median)a
62.5% (IQR, 27.5%–88.1%) 68.2% (IQR, 51%–85.7%) −5.7% (95% CI, −26.6 to 15.2) 0.39b
Proportion JC WMLs with
central veins (median)a
42.9% (IQR, 0%–100%) 66.7% (IQR, 28.6%–100%) −23.9% (95% CI, −69.4 to 21.7) 0.1
Abbreviations: DWM= deepwhitematter; IQR = interquartile range; JC = juxtacortical; PPMS = primary progressiveMS; PV = periventricular; RRMS = relapsing
remitting MS; WML = white matter lesion.
Mann-Whitney U test used to calculate p values, unless otherwise stated.
a Proportion of WMLs with central veins according to their location was calculated using the total number of WMLs in the same location as the denominator.
b Independent t test used.
c Calculated using Cohen d.
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more commonly seen with advancing age, one would have
expected a higher number of non-MS WMLs without a central
vein in the older PPMS group.32 However, the diﬀerence in the
proportion of WMLs with central veins between PPMS and
RRMS groups was not statistically diﬀerent. Infratentorial
WMLswere also not analyzed as we detected very few lesions in
this region using the T2* sequence (3 in PPMS, 2 in RRMS, and
3 in SVD groups). This is possibly a limitation of T2* in this
location. Despite this, as the proportion of WMLs with central
veins in the supratentorial brain was high for both MS groups,
the exclusion of a few infratentorial lesions probably would not
aﬀect the overall ability to diﬀerentiate MS from SVD. Addi-
tionally, our study did not use the central vein marker in
patients with PPMS or SVD at disease onset. A prospective
study in the diﬃcult to diagnose phenotype needs to validate
our cross-sectional central vein data. This is currently underway
at our institution. Furthermore, if the central vein marker ever
entered clinical practice, training for clinicians reporting scans
would be needed if, for example, the North American Imaging
in Multiple Sclerosis consensus criteria22 are used.
A number of centers have reported that fused images (e.g.,
FLAIR*) qualitatively can detect infratentorial lesions with
central veins reliably.35,38 Similarly, some advocate the use of
contrast agents in the detection of the central vein. No doubt
over the next few years, more speciﬁc MRI sequences and
reﬁnement of the central vein criteria will be developed op-
timizing the use of this new MRI sign. We would expect
similar or larger diﬀerences between the MS and non-MS
groups of patients with any improved methods.
Our ﬁndings show that WML central veins are present in
PPMS patients in as high proportions as those found in
RRMS. These can be identiﬁed in WMLs irrespective of the
chronicity of the disease using 3T, noncontrast T2*-weighted
imaging. The diﬀerence in these proportions between PPMS
and SVD patients is signiﬁcant, irrespective of supratentorial
brain location, and may be helpful in the clinical setting when
there is diﬃculty in diﬀerentiating these 2 conditions, clini-
cally or radiologically.
In this article, we wanted to demonstrate the clear potential of
the WML central vein marker in the diﬀerentiation of PPMS
from SVD using clinical scanners. The exact methodology
used by neuroradiologists in clinical practice will depend on
the gradually accumulating clinical experience, as the central
vein marker is increasingly being used by diﬀerent centers.
Speciﬁc prospective studies assessing the minimum number
of WMLs required to be assessed in patients with diagnostic
uncertainty need to be undertaken. Additionally, studies
comparing the diagnostic beneﬁt of the central vein marker to
the recent 2017 McDonald criteria would be important to
perform, alongside comparing its use to other current
diagnostic tests, e.g., CSF oligoclonal bands, spinal cord
inﬂammatory lesions and using a higher number of WMLs for
dissemination in space.
Using noncontrast T2* imaging and clinical 3TMRI scanners,
present now in many large hospitals worldwide, we can detect
the central vein marker inmuch higher proportions in patients
with PPMS and RRMS compared to patients with SVD. This
could be diagnostically useful. The newMS diagnostic criteria
strengthen the value of lumbar punctures in the diagnosis of
MS.19 Not all patients of course are keen or willing to have
a lumbar puncture. One can speculate that the WML central
vein marker might possibly oﬀer a noninvasive alternative to
lumbar puncture if the diagnosis is in doubt. That of course
would require conﬁrmation by a speciﬁc study.
Figure 3 Distribution of WMLs with central veins in the PV, DWM, and JC regions
DWM = deep white matter; JC = juxtacortical;
PPMS = primary progressive MS; PV = peri-
ventricular; RRMS = relapsing-remitting MS;
SVD = small vessel disease; WML = white mat-
ter lesion.
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